Authors
Latest:
Still Learning: Optimizing the Diagnosis and Screening of Respiratory VirusesWhile the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.
Latest:
When Should We De-Escalate Empiric Antimicrobials?De-escalating empiric antimicrobial therapy is a strategy to combat antimicrobial resistance. Antimicrobial stewardship programs can play a major role in preserving antibiotic effectiveness and preventing unnecessary antibiotic use.
Latest:
SHARE the Responsibility of Antibiotic Stewardship With Our PatientsHow pharmacists can use shared decision-making to improve antibiotic use.
Latest:
Respiratory Syncytial Viral Infection: Treatment With Ziresovir in InfantsFindings from a recent phase 3 trial show promising results for the approval of ziresovir in the treatment of respiratory syncytial virus in infants.
Latest:
A Day Late and a Dollar Short: Managing Antimicrobial Drug ShortagesWith antimicrobial drug shortages expected to continue globally, developing mitigation strategies is essential to prevent complications, including antimicrobial resistance.
Latest:
Practice Pearls for Treatment of Respiratory InfectionsTina Tan, MD; Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; Priya Nori, MD; Jacinda Abdul-Mutakabbir, PharmD; and Kevin Michael Reiter, MD, PA, provide key takeaways from the discussion on the treatment of respiratory viral infections.
Latest:
Multidisciplinary Perspectives on HIV TreatmentA multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
Latest:
The Pendulum of Progress: Soft Skills in Whole Person Clinical TrainingThese skills are as critical as ever, and younger clinicians and learners need them to communicate and work professionally.
Latest:
The Role of Antimicrobial Stewardship in the Treatment of C difficileBiologics have become a novel treatment in recurrent C. difficile.
Latest:
Challenges in the Management of Mycobacterium abscessus ComplexThis pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.
Latest:
Supporting Patients With HIVAdvice to community physicians regarding ways to enhance patient-provider relationships and navigate barriers that impact the management of HIV infections.
Latest:
Correcting the Lack of Diversity in Clinical Trials With Community-Based StudiesAmmara Mushtaq, MD, discusses the underrepresentation of different races during the pandemic, but also the newer efforts to include and represent these communities in smaller, local studies.
Latest:
Updates in the Treatment of Mycobacterium TuberculosisThe latest Bench to Bedside column reviews new guidance on the treatment of drug-susceptible and drug-resistance Mycobacterium tuberculosis infections.
Latest:
Reduced-Dose Trimethoprim-Sulfamethoxazole Effective in Treating Mild to Moderate Pneumocystis jirovecii PneumoniaHere is a review of using this therapy in this patient population.
Latest:
In These COVID 19 Times, Can We Reduce Hospitalizations Due to Skin Infections?Shortages of health care workers and an increase in COVID-19 cases has put a severe strain on the health care system. Thus, the opportunity to reduce the hospitalizations for other conditions and expand outpatient treatment opportunities should be welcomed.
Latest:
Reducing Peripheral Venous Catheter InfectionsLack of data may mean bloodstream infections caused by PVCs are an overlooked cause of morbidity in hospitalized patients.
Latest:
Warmer Winters Are Fueling a Surge in Tick-Borne IllnessesAndrew Lover, PhD, MPH, discusses the shifting landscape of tick-borne illnesses during Tick-Borne Disease Awareness Month.
Latest:
Kalihinol Analog Targets Apicoplast Function In Malaria TreatmentKarine G. Le Roch, PhD, discussed her research on a kalihinol analog that combats drug resistance in malaria, emphasizing the need for innovative treatments in the context of climate change and rising transmission rates.
Latest:
Final Diagnosis: Pott Puffy Tumor With Subdural EmpyemaA rare case of Pott puffy tumor occurs in an atypical patient with no risk factors, likely due to untreated sinus infection.
Latest:
Deciphering When to Use New Novel Agents in Clinical PracticeAthena Hobbs, PharmD, BCIDP, looked at this issue through the lens of treating urinary tract infections (UTI).
Latest:
Evaluating Safety and Efficacy of Vaxart's Oral Vaccine's Impact on COVID-19 VariantsPart 2 with James F Cummings, MD, as he discusses the need for a stronger response to emerging variants, the importance of protecting high-risk populations, and the potential to reduce vaccine hesitancy through easier administration.
Latest:
“Triple Therapy” Facing Triple ThreatClinicians provide an overview of intraamniotic infections and offer treatment strategies for these challenging infections.
Latest:
The Underlying Threat of Multidrug-Resistant Pathogens in the COVID-19 EraOver half of patients admitted with positive SARS-CoV-2 testing received antibiotics, but evidence of bacterial infection is uncovered in far fewer cases. We may already be seeing the effects of antibiotic overprescribing.
Latest:
Biden Administration Unveils HCV Initiative: A Significant Step Towards Public HealthThe federal government is working to provide greater access to testing and treatment.
Latest:
Shifting to Shorter Courses of Antibiotic Therapy for Common Pediatric InfectionsIn the latest SIDP column, two clinicians provide information on recent studies and guidelines directed at antibiotic durations in this patient population.
Latest:
Investigational Hepatitis D Therapy Well-Tolerated, Safe for Chronic Disease at Week 48In a study evaluating bulevirtide as monotherapy, investigators found the antiviral to be safe and tolerable following nearly a year of treatment.
Latest:
Sepsis Awareness Month: Highlighting the Findings from BLINGIIIContinuous antibiotic infusions show positive results and may improve outcomes for patients with severe sepsis.
Latest:
Differentiating Between DNA and mRNA PlatformsAmi Patel, PhD, provides insights on both technologies and how her research center, the Wistar Institute, is involved in DNA vaccine and monoclonal antibody research.
Latest:
Sticking It to COVID-19: The Expansion of the Pfizer-BioNTech Vaccine EUAA review of the data and circumstances that led to authorization in children ages 5 to 11 years.
